MYEOV is a prognostic factor in multiple myeloma
نویسندگان
چکیده
منابع مشابه
MYEOV is a prognostic factor in multiple myeloma.
OBJECTIVE Multiple myeloma is a plasma cell neoplasm characterized by the accumulation of malignant plasma cells within the bone marrow. This disease remains incurable despite major treatment improvements. However, gene expression profiling of multiple myeloma cells (MMC) may lead to identification of new therapeutic targets. MATERIALS AND METHODS Using Affymetrix microarrays, we identified t...
متن کاملHypodiploidy is a major prognostic factor in multiple myeloma.
Conventional karyotypes performed before any treatment in 208 patients with multiple myeloma were reviewed by the Groupe Français de Cytogénétique Hématologique. A total of 138 patients displayed complex chromosomal abnormalities (CCAs). According to the chromosome number pattern, a first group of 75 patients had a hyperdiploid karyotype. A second group of 63 patients referred to as the hypodip...
متن کاملCD200 is a new prognostic factor in multiple myeloma.
Using Affymetrix microarrays, we identified the expression of the CD200 gene in multiple myeloma cells (MMCs) of 112 patients with newly diagnosed multiple myeloma (MM). The CD200 gene was either absent or present (Affymetrix call) in 22% and 78% of MMCs, respectively. The CD200 gene is not expressed in cells of the patients' bone marrow (BM). CD200 is a membrane glycoprotein that imparts an im...
متن کاملA Tentative Staging of Multiple Myeloma by Utilizing Respective Coefficients of Prognostic Factors
Introduction: Multiple myeloma is a heterogeneous disease with different survival times among patients. Accurate prediction of prognosis in multiple myeloma is essential, as patients with a shorter survival time may require early bone marrow transplantation (BMT) and more advanced chemotherapy as a part of their first-line treatment. In the present study, a parameter, depicted by ga...
متن کاملA Tentative Staging of Multiple Myeloma by Utilizing Respective Coefficients of Prognostic Factors
Introduction: Multiple myeloma is a heterogeneous disease with different survival times among patients. Accurate prediction of prognosis in multiple myeloma is essential, as patients with a shorter survival time may require early bone marrow transplantation (BMT) and more advanced chemotherapy as a part of their first-line treatment. In the present study, a parameter, depicted by ga...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Experimental Hematology
سال: 2010
ISSN: 0301-472X
DOI: 10.1016/j.exphem.2010.09.002